Harnessing CD47 mimicry to inhibit phagocytic clearance and enhance anti-tumor efficacy of nanoliposomal doxorubicin

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440.
   PubMed Web of Science ®Google Scholar
• Jing L, Yang M, Li Y, et al. Metallothionein prevents doxorubicin cardiac toxicity by indirectly regulating the uncoupling proteins 2. Food Chem Toxicol. 2017 Dec;110:204–213. PubMed PMID: 29061315; eng.
   PubMed Web of Science ®Google Scholar
• Wu J, Tang C, Yin C. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy. Acta Biomater. 2017 Jan 1;47:81–90. PubMed PMID: 27729232; eng.
   PubMed Web of Science ®Google Scholar
• Wu R, Wang HL, Yu HL, et al. Doxorubicin toxicity changes myocardial energy metabolism in rats. Chem Biol Interact. 2016 Jan;25(244):149–158. PubMed PMID: 26721193; eng.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
   PubMed Web of Science ®Google Scholar
• Li S-D, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochimi Biophys Acta (BBA) Biomembr. 2009;1788(10):2259–2266.
   PubMed Web of Science ®Google Scholar
• Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2012;64:246–255.
   Web of Science ®Google Scholar
• Hilger RA, Richly H, Grubert M, et al. Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil. Int J Clin Pharmacol Ther. 2005 Dec;43(12):588–589. PubMed PMID: 16372528; eng.
   PubMedGoogle Scholar
• Twelves CJ, Dobbs NA, Aldhous M, et al. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol. 1991;28(4):302–307. PubMed PMID: 1879047; eng.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs. 1997;54 Suppl 4:15–21. PubMed PMID: 9361957; eng.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994 Feb 15;54(4):987–992. PubMed PMID: 8313389; eng.
   PubMed Web of Science ®Google Scholar
• Hong RL, Huang CJ, Tseng YL, et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res off J Am Assoc Cancer Res. 1999 Nov;5(11):3645–3652. PubMed PMID: 10589782; eng
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Akita H, Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull. 2013;36(6):892–899.
   PubMed Web of Science ®Google Scholar
• Matozaki T, Murata Y, Okazawa H, et al. Functions and molecular mechanisms of the CD47–SIRPα signalling pathway. Trends Cell Biol. 2009;19(2):72–80.
   PubMed Web of Science ®Google Scholar
• Liu X, Kwon H, Li Z, et al. Is CD47 an innate immune checkpoint for tumor evasion? J Hematol Oncol. 2017;10(1):12.
   PubMed Web of Science ®Google Scholar
• Hayat SMG, Bianconi V, Pirro M, et al. CD47: role in the immune system and application to cancer therapy. Cell Oncol (Dordr). 2020 Feb;43(1):19-30. PMID: 31485984.
   Google Scholar
• Liu Y, O’Connor MB, Mandell KJ, et al. Peptide-mediated inhibition of neutrophil transmigration by blocking CD47 interactions with signal regulatory protein alpha. J Immunol. 2004 Feb 15;172(4):2578–2585. PubMed PMID: 14764731; eng.
   PubMed Web of Science ®Google Scholar
• Woodle MC, Papahadjopoulos D. Liposome preparation and size characterization. Methods Enzymol. 1989;171:193–217. PubMed PMID: 2593841; eng
   PubMed Web of Science ®Google Scholar
• Arabi L, Badiee A, Mosaffa F, et al. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. J Control Release. 2015 Dec 28;220(Pt A):275–286. PubMed PMID: 26518722; eng.
   PubMed Web of Science ®Google Scholar
• Alibolandi M, Taghdisi SM, Ramezani P, et al. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo. Int J Pharm. 2017 Mar 15;519(1–2):352–364. PubMed PMID: 28126548; eng.
   PubMed Web of Science ®Google Scholar
• Huang Z, Jaafari MR, Szoka FC Jr. Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery. Angew Chem (Int Ed in English). 2009;48(23):4146–4149. PubMed PMID: 19425026; PubMed Central PMCID: PMCPMC2773798. eng.
   PubMed Web of Science ®Google Scholar
• Huang Z, Szoka FC Jr. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties. J Am Chem Soc. 2008 Nov 19;130(46):15702–15712. PubMed PMID: 18950160; PubMed Central PMCID: PMCPMC2701441. eng.
   PubMed Web of Science ®Google Scholar
• Huang SK, Mayhew E, Gilani S, et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992;52(24):6774–6781.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huo M, Zhou J, et al. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010 Sep;99(3):306–314. PubMed PMID: 20176408; eng.
   PubMed Web of Science ®Google Scholar
• Gheibi Hayat SM, Bianconi V, Pirro M, et al. Efferocytosis: molecular mechanisms and pathophysiological perspectives. Immunol Cell Biol. 2019 Feb;97(2):124–133. PubMed PMID: 30230022; eng.
   PubMed Web of Science ®Google Scholar
• Tsai RK, Discher DE. Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008 Mar 10;180(5):989–1003. PubMed PMID: 18332220; PubMed Central PMCID: PMCPMC2265407. eng.
   PubMed Web of Science ®Google Scholar
• Bruns H, Bessell C, Varela JC, et al. CD47 enhances in vivo functionality of artificial antigen-presenting cells. Clin Cancer Res off J Am Assoc Cancer Res. 2015 May 1;21(9):2075–2083. PubMed PMID: 25593301; PubMed Central PMCID: PMCPMC4417460. eng.
   PubMed Web of Science ®Google Scholar
• Hayat SMG, Jaafari MR, Hatamipour M, et al. Liposome circulation time is prolonged by CD47 coating. Protein Pept Lett. 2020 Apr 12. PubMed PMID: 32282292; eng. DOI:10.2174/0929866527666200413100120.
   PubMed Web of Science ®Google Scholar
• Tsai RK, Rodriguez PL, Discher DE. Self inhibition of phagocytosis: the affinity of ‘marker of self’ CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis. 2010 Jun 15;45(1):67–74. PubMed PMID: 20299253; PubMed Central PMCID: PMCPMC2878922. eng.
   PubMed Web of Science ®Google Scholar
• Hayat SMG, Bianconi V, Pirro M, et al. Stealth functionalization of biomaterials and nanoparticles by CD47 mimicry. Int J Pharm. 2019 Oct 5;569:118628.PMID: 31421198.
   Google Scholar